ProShares UltraShort Silver

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

Direxion Daily Gold Miners Bear 3X ETF

Direxion Daily Semicondct Bull 3X ETF

ProShares Bitcoin Strategy ETF

Defiance Daily Short Digitizing the Economy ETF

Altimmune Inc. Common Stock

ProShares UltraPro QQQ

Direxion Daily 20+ Yr Trsy Bear 3X ETF

Direxion Daily Technology Bull 3X ETF

Guggenheim Solar ETF

ProShares Ultra Silver

MicroSectors Gold Miners 3X Leveraged ETN

iShares Silver Trust

Direxion Daily Gold Miners Bull 3X ETF

Direxion Daily Semicondct Bear 3X ETF

ProShares Trust ProShares Short Bitcoin Strategy ETF

VS TR 2x Long VIX Futures ETF

SPDR S&P Regional Banking ETF

United States Oil Fund

Navitas Semiconductor Corporation Common Stock

Urban Outfitters Inc. Common Stock

Snowflake Inc. Class A Common Stock

MINISO Group Holding Limited American Depositary Shares each representing four Ordinary Shares

CleanSpark Inc. Common Stock

AgEagle Aerial Systems Inc. Common Stock

Aquestive Therapeutics Inc. Common Stock

Marathon Digital Holdings Inc. Common Stock

Riot Platforms Inc. Common Stock

Analog Devices Inc. Common Stock

Fastenal Company Common Stock

Edible Garden AG Incorporated Common Stock

SolarEdge Technologies Inc. Common Stock

Enphase Energy Inc. Common Stock

Hims & Hers Health Inc. Class A Common Stock

XPeng Inc. American depositary shares each representing two Class A ordinary shares

Virgin Galactic Holdings Inc. Common Stock

IBO (Listing Market - NYSE Amex Network B F)

CVS Health Corporation Common Stock

UnitedHealth Group Incorporated Common Stock (DE)

Click here to get full coverage on New Analyst Forecast: $RCKT Given 'Overweight' Rating - Nasdaq

New Analyst Forecast: $RCKT Given 'Overweight' Rating  Nasdaq

New Analyst Forecast: $RCKT Given 'Overweight' Rating - Nasdaq

Click here to get full coverage on RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus - Yahoo Finance

RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus  Yahoo Finance

RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus - Yahoo Finance

Click here to get full coverage on Is Rocket Pharmaceuticals (RCKT) the Best Low Priced Biotech Stock to Buy Now? - MSN

Is Rocket Pharmaceuticals (RCKT) the Best Low Priced Biotech Stock to Buy Now?  MSN

Is Rocket Pharmaceuticals (RCKT) the Best Low Priced Biotech Stock to Buy Now? - MSN

Click here to get full coverage on Rocket Pharma Out Of Orbit, But Ready For Re-Launch (NASDAQ:RCKT) - Seeking Alpha

Rocket Pharma Out Of Orbit, But Ready For Re-Launch (NASDAQ:RCKT)  Seeking Alpha

Rocket Pharma Out Of Orbit, But Ready For Re-Launch (NASDAQ:RCKT) - Seeking Alpha

Click here to get full coverage on Rocket Pharmaceuticals (RCKT) Price Target Raised by Cantor Fitz - GuruFocus

Rocket Pharmaceuticals (RCKT) Price Target Raised by Cantor Fitz  GuruFocus

Rocket Pharmaceuticals (RCKT) Price Target Raised by Cantor Fitz - GuruFocus

Click here to get full coverage on Cantor Fitzgerald lifts RCKT stock target to $30 on positive data - Investing.com

Cantor Fitzgerald lifts RCKT stock target to $30 on positive data  Investing.com

Cantor Fitzgerald lifts RCKT stock target to $30 on positive data - Investing.com

Click here to get full coverage on Rocket Pharmaceuticals (RCKT) Tops Q1 EPS by 3c - StreetInsider

Rocket Pharmaceuticals (RCKT) Tops Q1 EPS by 3c  StreetInsider

Rocket Pharmaceuticals (RCKT) Tops Q1 EPS by 3c - StreetInsider

Click here to get full coverage on Insider Purchase: CEO of $RCKT Buys 20,000 Shares - Nasdaq

Insider Purchase: CEO of $RCKT Buys 20,000 Shares  Nasdaq

Insider Purchase: CEO of $RCKT Buys 20,000 Shares - Nasdaq

Click here to get full coverage on Rocket Pharmaceuticals (RCKT): Among Stocks Under $10 that Will Triple - Yahoo Finance

Rocket Pharmaceuticals (RCKT): Among Stocks Under $10 that Will Triple  Yahoo Finance

Rocket Pharmaceuticals (RCKT): Among Stocks Under $10 that Will Triple - Yahoo Finance

Click here to get full coverage on Rocket Pharmaceuticals (RCKT) Price Target Maintained by Wedbush | RCKT Stock News - GuruFocus

Rocket Pharmaceuticals (RCKT) Price Target Maintained by Wedbush | RCKT Stock News  GuruFocus

Rocket Pharmaceuticals (RCKT) Price Target Maintained by Wedbush | RCKT Stock News - GuruFocus

Click here to get full coverage on Cantor Fitzgerald lifts RCKT stock target to $30 on positive data - Investing.com Nigeria

Cantor Fitzgerald lifts RCKT stock target to $30 on positive data  Investing.com Nigeria

Cantor Fitzgerald lifts RCKT stock target to $30 on positive data - Investing.com Nigeria

Click here to get full coverage on Is Rocket Pharmaceuticals (NASDAQ:RCKT) In A Good Position To Deliver On Growth Plans? - Yahoo Finance

Is Rocket Pharmaceuticals (NASDAQ:RCKT) In A Good Position To Deliver On Growth Plans?  Yahoo Finance

Is Rocket Pharmaceuticals (NASDAQ:RCKT) In A Good Position To Deliver On Growth Plans? - Yahoo Finance

Click here to get full coverage on $RCKT stock is up 9% today. Here's what we see in our data. - Nasdaq

$RCKT stock is up 9% today. Here's what we see in our data.  Nasdaq

$RCKT stock is up 9% today. Here's what we see in our data. - Nasdaq

Click here to get full coverage on Rocket Pharmaceuticals (RCKT) Price Target Raised by Chardan Capital | RCKT Stock News - GuruFocus

Rocket Pharmaceuticals (RCKT) Price Target Raised by Chardan Capital | RCKT Stock News  GuruFocus

Rocket Pharmaceuticals (RCKT) Price Target Raised by Chardan Capital | RCKT Stock News - GuruFocus

Click here to get full coverage on Rocket Pharmaceuticals, Inc. (RCKT): A Bull Case Theory - Yahoo Finance

Rocket Pharmaceuticals, Inc. (RCKT): A Bull Case Theory  Yahoo Finance

Rocket Pharmaceuticals, Inc. (RCKT): A Bull Case Theory - Yahoo Finance

Click here to get full coverage on When Will Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Turn A Profit? - Yahoo Finance

When Will Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Turn A Profit?  Yahoo Finance

When Will Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Turn A Profit? - Yahoo Finance

Click here to get full coverage on Rocket Pharmaceuticals (RCKT) Sees Price Target Boost Amid Positive Trial Data | RCKT Stock News - GuruFocus

Rocket Pharmaceuticals (RCKT) Sees Price Target Boost Amid Positive Trial Data | RCKT Stock News  GuruFocus

Rocket Pharmaceuticals (RCKT) Sees Price Target Boost Amid Positive Trial Data | RCKT Stock News - GuruFocus

Click here to get full coverage on Chardan Ups Price Target for Rocket Pharmaceuticals (RCKT) | RCKT Stock News - GuruFocus

Chardan Ups Price Target for Rocket Pharmaceuticals (RCKT) | RCKT Stock News  GuruFocus

Chardan Ups Price Target for Rocket Pharmaceuticals (RCKT) | RCKT Stock News - GuruFocus

Click here to get full coverage on BMO Capital Initiates Coverage of Rocket Pharmaceuticals (RCKT) with Outperform Recommendation - Nasdaq

BMO Capital Initiates Coverage of Rocket Pharmaceuticals (RCKT) with Outperform Recommendation  Nasdaq

BMO Capital Initiates Coverage of Rocket Pharmaceuticals (RCKT) with Outperform Recommendation - Nasdaq

Click here to get full coverage on Rocket Pharma's Gene Therapy Shows Promise in ACM Patients, Says Analyst - Benzinga

Rocket Pharma's Gene Therapy Shows Promise in ACM Patients, Says Analyst  Benzinga

Rocket Pharma's Gene Therapy Shows Promise in ACM Patients, Says Analyst - Benzinga

Click here to get full coverage on Rocket Pharmaceuticals, Inc. (RCKT): Is This Gene Therapy Stock a Good Buy Right Now? - Yahoo Finance

Rocket Pharmaceuticals, Inc. (RCKT): Is This Gene Therapy Stock a Good Buy Right Now?  Yahoo Finance

Rocket Pharmaceuticals, Inc. (RCKT): Is This Gene Therapy Stock a Good Buy Right Now? - Yahoo Finance

Click here to get full coverage on Insider Purchase: See Remarks of $RCKT Buys 21,099 Shares - Nasdaq

Insider Purchase: See Remarks of $RCKT Buys 21,099 Shares  Nasdaq

Insider Purchase: See Remarks of $RCKT Buys 21,099 Shares - Nasdaq

Click here to get full coverage on Rocket Pharmaceuticals (RCKT) Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy - StreetInsider

Rocket Pharmaceuticals (RCKT) Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy  StreetInsider

Rocket Pharmaceuticals (RCKT) Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy - StreetInsider

Click here to get full coverage on Gene Therapy Trial Shows 398% Protein Boost in Rare Heart Disease Patients | RCKT Stock News - Stock Titan

Gene Therapy Trial Shows 398% Protein Boost in Rare Heart Disease Patients | RCKT Stock News  Stock Titan

Gene Therapy Trial Shows 398% Protein Boost in Rare Heart Disease Patients | RCKT Stock News - Stock Titan

Click here to get full coverage on Gene Therapy Pioneer Rocket Pharmaceuticals Secures Funding Through 2026 Despite Wider Losses - Stock Titan

Gene Therapy Pioneer Rocket Pharmaceuticals Secures Funding Through 2026 Despite Wider Losses  Stock Titan

Gene Therapy Pioneer Rocket Pharmaceuticals Secures Funding Through 2026 Despite Wider Losses - Stock Titan

Click here to get full coverage on Is Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) the Best US Stock Under $10 to Buy Right Now? - Yahoo Finance

Is Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) the Best US Stock Under $10 to Buy Right Now?  Yahoo Finance

Is Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) the Best US Stock Under $10 to Buy Right Now? - Yahoo Finance

Click here to get full coverage on (RCKT) Investment Analysis - news.stocktradersdaily.com

(RCKT) Investment Analysis  news.stocktradersdaily.com

(RCKT) Investment Analysis - news.stocktradersdaily.com

Click here to get full coverage on Rocket Pharmaceuticals (RCKT) Phase 1 Trial Yields Promising Res - GuruFocus

Rocket Pharmaceuticals (RCKT) Phase 1 Trial Yields Promising Res  GuruFocus

Rocket Pharmaceuticals (RCKT) Phase 1 Trial Yields Promising Res - GuruFocus

Click here to get full coverage on Rocket Pharmaceuticals (RCKT) Sees Price Target Adjustment by JP Morgan | RCKT Stock News - GuruFocus

Rocket Pharmaceuticals (RCKT) Sees Price Target Adjustment by JP Morgan | RCKT Stock News  GuruFocus

Rocket Pharmaceuticals (RCKT) Sees Price Target Adjustment by JP Morgan | RCKT Stock News - GuruFocus

Click here to get full coverage on Rock Tech's designation as "Strategic Project" by the European Commission is considered a "Transformational Milestone" - Only three Lithium projects in Germany were selected - Rock Tech is the only full-scale European Lithium refinery using proven and test - PR Newswire

Rock Tech's designation as "Strategic Project" by the European Commission is considered a "Transformational Milestone" - Only three Lithium projects in Germany were selected - Rock Tech is the only full-scale European Lithium refinery using proven and test  PR Newswire

Rock Tech's designation as "Strategic Project" by the European Commission is considered a "Transformational Milestone" - Only three Lithium projects in Germany were selected - Rock Tech is the only full-scale European Lithium refinery using proven and test - PR Newswire

Click here to get full coverage on RCKT: Scotiabank Lowers Price Target for Rocket Pharmaceuticals to $51 | RCKT Stock News - GuruFocus

RCKT: Scotiabank Lowers Price Target for Rocket Pharmaceuticals to $51 | RCKT Stock News  GuruFocus

RCKT: Scotiabank Lowers Price Target for Rocket Pharmaceuticals to $51 | RCKT Stock News - GuruFocus

Click here to get full coverage on Canaccord Revises Rocket Pharmaceuticals (RCKT) Price Target Ami - GuruFocus

Canaccord Revises Rocket Pharmaceuticals (RCKT) Price Target Ami  GuruFocus

Canaccord Revises Rocket Pharmaceuticals (RCKT) Price Target Ami - GuruFocus

Click here to get full coverage on JPMorgan Adjusts Price Target for Rocket Pharmaceuticals (RCKT) | RCKT Stock News - GuruFocus

JPMorgan Adjusts Price Target for Rocket Pharmaceuticals (RCKT) | RCKT Stock News  GuruFocus

JPMorgan Adjusts Price Target for Rocket Pharmaceuticals (RCKT) | RCKT Stock News - GuruFocus

Click here to get full coverage on Chardan Capital Lowers Price Target for RCKT to $45, Maintains Buy Rating | RCKT Stock News - GuruFocus

Chardan Capital Lowers Price Target for RCKT to $45, Maintains Buy Rating | RCKT Stock News  GuruFocus

Chardan Capital Lowers Price Target for RCKT to $45, Maintains Buy Rating | RCKT Stock News - GuruFocus

Click here to get full coverage on Rocket Pharmaceuticals (RCKT) Loses -12.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

Rocket Pharmaceuticals (RCKT) Loses -12.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner  Yahoo Finance

Rocket Pharmaceuticals (RCKT) Loses -12.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

Click here to get full coverage on Rocket Pharmaceuticals (RCKT) Maintains 'Buy' Rating Despite PT Reduction | RCKT Stock News - GuruFocus

Rocket Pharmaceuticals (RCKT) Maintains 'Buy' Rating Despite PT Reduction | RCKT Stock News  GuruFocus

Rocket Pharmaceuticals (RCKT) Maintains 'Buy' Rating Despite PT Reduction | RCKT Stock News - GuruFocus

Click here to get full coverage on Rocket Pharmaceuticals (RCKT) Price Target Lowered by Goldman Sa - GuruFocus

Rocket Pharmaceuticals (RCKT) Price Target Lowered by Goldman Sa  GuruFocus

Rocket Pharmaceuticals (RCKT) Price Target Lowered by Goldman Sa - GuruFocus

Click here to get full coverage on Scotiabank Adjusts Price Target for Rocket Pharmaceuticals (RCKT) | RCKT Stock News - GuruFocus

Scotiabank Adjusts Price Target for Rocket Pharmaceuticals (RCKT) | RCKT Stock News  GuruFocus

Scotiabank Adjusts Price Target for Rocket Pharmaceuticals (RCKT) | RCKT Stock News - GuruFocus

Click here to get full coverage on Rocket Pharmaceuticals: Q1 Earnings Snapshot - News-Times

Rocket Pharmaceuticals: Q1 Earnings Snapshot  News-Times

Rocket Pharmaceuticals: Q1 Earnings Snapshot - News-Times

Click here to get full coverage on Rocket Pharmaceuticals (RCKT) Price Target Lowered by Goldman Sachs | RCKT Stock News - GuruFocus

Rocket Pharmaceuticals (RCKT) Price Target Lowered by Goldman Sachs | RCKT Stock News  GuruFocus

Rocket Pharmaceuticals (RCKT) Price Target Lowered by Goldman Sachs | RCKT Stock News - GuruFocus

Click here to get full coverage on RCKT stock touches 52-week low at $8.22 amid market challenges - Investing.com

RCKT stock touches 52-week low at $8.22 amid market challenges  Investing.com

RCKT stock touches 52-week low at $8.22 amid market challenges - Investing.com

Click here to get full coverage on Here's Why We're Watching Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Situation - Yahoo Finance

Here's Why We're Watching Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Situation  Yahoo Finance

Here's Why We're Watching Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Situation - Yahoo Finance

Click here to get full coverage on Rocket Pharmaceuticals Secures $165M Through Upsized Public Stock Offering at $12.50 Per Share - Stock Titan

Rocket Pharmaceuticals Secures $165M Through Upsized Public Stock Offering at $12.50 Per Share  Stock Titan

Rocket Pharmaceuticals Secures $165M Through Upsized Public Stock Offering at $12.50 Per Share - Stock Titan

Click here to get full coverage on Cantor Fitzgerald lifts RCKT stock target to $30 on positive data - Investing.com UK

Cantor Fitzgerald lifts RCKT stock target to $30 on positive data  Investing.com UK

Cantor Fitzgerald lifts RCKT stock target to $30 on positive data - Investing.com UK

Click here to get full coverage on Insider Sale: Chief Financial Officer of $RCKT Sells 7,489 Shares - Nasdaq

Insider Sale: Chief Financial Officer of $RCKT Sells 7,489 Shares  Nasdaq

Insider Sale: Chief Financial Officer of $RCKT Sells 7,489 Shares - Nasdaq

Click here to get full coverage on Rocket Pharma Is A Buy At These Prices With Promising Data (NASDAQ:RCKT) - Seeking Alpha

Rocket Pharma Is A Buy At These Prices With Promising Data (NASDAQ:RCKT)  Seeking Alpha

Rocket Pharma Is A Buy At These Prices With Promising Data (NASDAQ:RCKT) - Seeking Alpha

Click here to get full coverage on RCKT stock touches 52-week low at $9.76 amid market challenges - MSN

RCKT stock touches 52-week low at $9.76 amid market challenges  MSN

RCKT stock touches 52-week low at $9.76 amid market challenges - MSN

Click here to get full coverage on Rocket Pharmaceuticals Director R. Keith Woods to Depart - TipRanks

Rocket Pharmaceuticals Director R. Keith Woods to Depart  TipRanks

Rocket Pharmaceuticals Director R. Keith Woods to Depart - TipRanks

Click here to get full coverage on Rocket Pharmaceuticals: Not Bad Valuation But Reflexivity Risks Remain (RCKT) - Seeking Alpha

Rocket Pharmaceuticals: Not Bad Valuation But Reflexivity Risks Remain (RCKT)  Seeking Alpha

Rocket Pharmaceuticals: Not Bad Valuation But Reflexivity Risks Remain (RCKT) - Seeking Alpha

Click here to get full coverage on Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock - Business Wire

Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock  Business Wire

Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock - Business Wire

Click here to get full coverage on Is Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) the Best US Stock Under $10 to Buy Right Now? - MSN

Is Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) the Best US Stock Under $10 to Buy Right Now?  MSN

Is Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) the Best US Stock Under $10 to Buy Right Now? - MSN

Click here to get full coverage on Friday 4/11 Insider Buying Report: RCKT - Nasdaq

Friday 4/11 Insider Buying Report: RCKT  Nasdaq

Friday 4/11 Insider Buying Report: RCKT - Nasdaq

Click here to get full coverage on BMO Capital: 'Rocket Pharmaceuticals (RCKT) Poised for an Asymmetric Rebound in 2Q25+' - StreetInsider

BMO Capital: 'Rocket Pharmaceuticals (RCKT) Poised for an Asymmetric Rebound in 2Q25+'  StreetInsider

BMO Capital: 'Rocket Pharmaceuticals (RCKT) Poised for an Asymmetric Rebound in 2Q25+' - StreetInsider

Click here to get full coverage on Pentair To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga

Pentair To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday  Benzinga

Rocket Pharmaceuticals Inc (RCKT)

Price Chart

Key Statistics

Technicals

About RCKT

Latest News

New Analyst Forecast: $RCKT Given 'Overweight' Rating - Nasdaq

RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus - Yahoo Finance

Is Rocket Pharmaceuticals (RCKT) the Best Low Priced Biotech Stock to Buy Now? - MSN

Advanced Charts

Top Gainers

Top Losers